Biomedical Engineering Reference
In-Depth Information
References
1. Human tissue intended for transplantation. Federal Register 68514. USA: Food and Drug Admin-
istration, 1993:58.
2. Application to current statutory authorities to human somatic cell therapy products and gene therapy
products. Federal Register 53248. USA: Food and Drug Administration, 1993:58.
3. De Luca M. Towards epidermal stem cell-mediated gene therapy. In: Migliaccio AR, Carta C,
Campisi S, eds. First international workshop on cell therapy: Filling the gap between basic science
and clinical trials. Abstract Book. Rome, Italy: Istituto Superiore di Sanità, 2001; 2.
4. Orkin SH, Motulsky AG. Report and recommendations of the panel to assess the NIH investment
in research on gene therapy. Dec 7th 1995:See the URL address: http://www.nih.gov/news/
panelrep.html
5. Grisham J. Inquiry in gene therapy widens. Nature Biotech 2000; 18:254.
6. Romano G, Michell P, Pacilio C et al. Latest developments in gene transfer technology: Achieve-
ments, perspectives and controversies over therapeutic applications. Stem Cells 2000; 18:19-39.
7. Barbour V. The balance of risk and benefit in gene therapy trials. Lancet 2000; 355:384.
8. Proposed approach to regulation of cellular and tissue-based products. Docket N. 97N-0068; Cen-
ter for Biologics Evaluation and Research. USA: Food and Drug Administration, 1997.
9. Weber DJ. FDA/CBER/OTRR RAPS. Oct 3rd 2000:See the URL address: http://www.fda.gov/
cber/guidelines.htm
10. Guidance on applications for products comprised of living autologous cells manipulated ex vivo
and intended for structural repair or reconstruction. Docket N. 95N-0200; Center for Biologics
Evaluation and Research. USA: Food and Drug Administration, 1996.
11. Massotti M. Linee guida per l'avvio di studi clinici di fase I/II con cellule umane viventi per la
terapia cellulare somatica. Notiziario dell'Istituto Superiore di Sanità 1997; 10(5):1-8.
12. Cancedda R, Chistolini P, Cossu G et al. Linee guida per l'ingegneria dei tessuti e la terapia
cellulare. Notiziario dell'Istituto Superiore di Sanità 1999; 12(5):1-8.
13. Ministerial Decree. Linee guida di riferimento per l'istituzione ed il funzionamento dei comitati
etici. Gazzetta Ufficiale della Repubblica Italiana, March 18th 1998:122.
14. Ministerial Decree. Attivazione delle Direttive 89/391, 89/654, 89/656, 90/269, 90/270, 90/394, e
90/679 CEE sul miglioramento della sicurezza e della salute dei lavoratori sul luogo di lavoro.
Gazzetta Ufficiale della Repubblica Italiana, September 19th 1994:265.
15. Elimination of establishment licence application for specified biotechnology and specified synthetic
biological products; 61 Federal Register 24227. USA Food and Drug Administration; 1994
16. Tissue Action Plan—Reinventing the regulation of human tissue. 1997:See the URL address: http:/
/www.fda.gov/cber/tissue/rego.htm
17. EN-ISO 14971 Medical devices: Risk Management—Application of Risk Management to Medical
Devices. 2000.
18. Dell'Accio F, De Bari C, Luyten FP. Molecular markers predictive of the capacity of expanded
human articular chondrocytes to form stable cartilage in vivo. Arthritis Rheum 2001;
44(7):1068-1619.
19. Migliaccio G. Valutazione di qualità dei prodotti per terapia cellulare. In: Massotti M and Meneguz
A, eds. Obiettivi e interprtetazione degli studi preclinici richiesti per avviare la sperimentazione
clinica di fase I. Rapporti ISTISAN 01/22. Rome: Istituto Superiore di Sanità, 2001:26-36.
20. Guidance for the submission of chemistry, manufacturing, and control information and establish-
ment description for autologous somatic cell therapy products. Docket N. 95N-0200; Center for
Biologics Evaluation and Research. USA: Food and Drug Administration, 1997.
21. Public Health Service Act, Section 361, Title 42 US Code; USA.
22. Korwek EL, Learn MD. Biologics update. Food and Drug Institute Update 2001; 2:4-6.
23. Noguchi PD. From Jim to gene and beyond: An odyssey of biologics regulation. Food and Drug
Law Journal 1996; 51:367-373.